Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/1998

01-05-1998 | ORIGINAL ARTICLE

Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis

Authors: Yoshiaki Fujimiya, Youichi Suzuki, Ko-ichi Oshiman, Hidekazu Kobori, Koichi Moriguchi, Hisako Nakashima, Yonezo Matumoto, Shogo Takahara, Takusaburo Ebina, Ryuichi Katakura

Published in: Cancer Immunology, Immunotherapy | Issue 3/1998

Login to get access
Metadata
Title
Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis
Authors
Yoshiaki Fujimiya
Youichi Suzuki
Ko-ichi Oshiman
Hidekazu Kobori
Koichi Moriguchi
Hisako Nakashima
Yonezo Matumoto
Shogo Takahara
Takusaburo Ebina
Ryuichi Katakura
Publication date
01-05-1998
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/1998
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050473

Other articles of this Issue 3/1998

Cancer Immunology, Immunotherapy 3/1998 Go to the issue

ORIGINAL ARTICLE

Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells

ORIGINAL ARTICLE

Nitric oxide inhibits proliferation but increases life-span of T lymphocytes in tumour-bearing rats

REVIEW

Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications

ORIGINAL ARTICLE

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

ORIGINAL ARTICLE

Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits